StockData

Kala Bio vs Oculis

KALA and OCS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KALA and OCS compare

Kala Bio scores higher on the StockData Score (5 against 1 for Oculis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKALAOCS
Size and price
Market cap$74.1M–
Share price$3.83$7.63
Change, 1 year−88.4%−60.4%
Change, 5 years−100.0%−21.4%
Beta (5Y)2.322.45
Employees660
StockData Score
Total score5 (better)1
Valuation score00
Growth score00
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/B8.2×–
Profitability
Return on equity−345%–
Financial health
Debt / equity0.00–
Interest coverage–−98.0×
Current ratio6.888.35 (better)
Altman Z-score−68.98–
Piotroski F-score2–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions3.2%–
Held by insiders–11.6%
Insider net buying, 12 months$0–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.